Skip to main content
Top
Published in: Hepatology International 1/2024

Open Access 19-09-2023 | Primary Biliary Cholangitis | Original Article

Prognostic significance of liver stiffness in patients with primary biliary cholangitis: validation of Baveno VII criteria

Authors: Dawei Ding, Guanya Guo, Lina Cui, Gui Jia, Xiufang Wang, Miao Zhang, Siyuan Tian, Linhua Zheng, Yansheng Liu, Yinan Hu, Guoyun Xuan, Jiaqi Yang, Chunmei Yang, Ruiqing Sun, Juan Deng, Changcun Guo, Yu Chen, Yulong Shang, Ying Han

Published in: Hepatology International | Issue 1/2024

Login to get access

Abstract

Background

The role of liver stiffness measurements (LSM) in patients with primary biliary cholangitis (PBC) remains to be further elucidated.

Aims

To clarify the prognostic role of LSM and to validate the “novel concepts” proposed by the Baveno VII Working Group.

Methods

An analysis of the prognostic significance of LSM was performed involving 672 patients.

Results

LSM and ΔLSM/ΔT were independent risk factors for liver decompensation, liver transplantation, or liver-related death (primary outcomes, p < 0.001, both). A rule of 5 kPa for LSM (10–15–20 kPa) could be used to denote progressively higher relative risks of primary outcomes. Patients with LSM < 10 kPa have a negligible 3-year risk of primary outcomes (< 1%). Cut-off values of 10 and 15 kPa can be used to classify PBC patients into low-, medium-, and high-risk groups. A clinically significant decrease in LSM, evaluated at 6, 12, or 24 months elastography tests, was associated with a substantially reduced risk of primary outcomes (p < 0.05, all), which can be defined as a decrease in LSM of >  − 20% associated with LSM < 20 kPa or any decrease to LSM < 10 kPa. A clinically significant increase in LSM, evaluated at 6, 12, or 24 months elastography tests, was associated with a substantially raised risk of primary outcomes (p < 0.05, all), which can be defined as an increase in LSM of ≥  + 20% or any increase to LSM ≥ 15 kPa.

Conclusions

LSM can be used to monitor disease progression and predict long-term prognosis in patients with PBC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Shang Y, Leung PSC, Gershwin ME, et al. Primary biliary cholangitis: personalized medicine for optimal therapeutic opportunities. Sci Bull (Beijing) 2022;67(24):2498–2501ADSCrossRefPubMed Shang Y, Leung PSC, Gershwin ME, et al. Primary biliary cholangitis: personalized medicine for optimal therapeutic opportunities. Sci Bull (Beijing) 2022;67(24):2498–2501ADSCrossRefPubMed
2.
go back to reference Azemoto N, Abe M, Murata Y, et al. Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis. J Gastroenterol 2009;44(6):630–634CrossRefPubMed Azemoto N, Abe M, Murata Y, et al. Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis. J Gastroenterol 2009;44(6):630–634CrossRefPubMed
3.
go back to reference Parés A, Caballería L, Rodés J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006;130(3):715–720CrossRefPubMed Parés A, Caballería L, Rodés J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006;130(3):715–720CrossRefPubMed
4.
go back to reference Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008;48(3):871–877CrossRefPubMed Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008;48(3):871–877CrossRefPubMed
5.
go back to reference Corpechot C, Chazouilleres O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol 2011;55(6):1361–1367CrossRefPubMed Corpechot C, Chazouilleres O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol 2011;55(6):1361–1367CrossRefPubMed
6.
go back to reference Kuiper EMM, Hansen BE, de Vries RA, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009;136(4):1281–1287CrossRefPubMed Kuiper EMM, Hansen BE, de Vries RA, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009;136(4):1281–1287CrossRefPubMed
7.
go back to reference Carbone M, Sharp SJ, Flack S, et al. The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. Hepatology 2016;63(3):930–950CrossRefPubMed Carbone M, Sharp SJ, Flack S, et al. The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. Hepatology 2016;63(3):930–950CrossRefPubMed
8.
go back to reference Lammers WJ, Hirschfield GM, Corpechot C, et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology 2015;149(7):1804CrossRefPubMed Lammers WJ, Hirschfield GM, Corpechot C, et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology 2015;149(7):1804CrossRefPubMed
9.
go back to reference Kumagi T, Guindi M, Fischer SE, et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol 2010;105(10):2186–2194CrossRefPubMed Kumagi T, Guindi M, Fischer SE, et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol 2010;105(10):2186–2194CrossRefPubMed
10.
go back to reference Yang C, Guo G, Li B, et al. Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion. Hepatol Int 2023;17(1):237–248CrossRefPubMed Yang C, Guo G, Li B, et al. Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion. Hepatol Int 2023;17(1):237–248CrossRefPubMed
11.
go back to reference Corpechot C, Carrat F, Poujol-Robert A, et al. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology 2012;56(1):198–208CrossRefPubMed Corpechot C, Carrat F, Poujol-Robert A, et al. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology 2012;56(1):198–208CrossRefPubMed
12.
go back to reference Corpechot C, Carrat F, Gaouar F, et al. Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. J Hepatol 2022;77(6):1545–1553CrossRefPubMed Corpechot C, Carrat F, Gaouar F, et al. Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. J Hepatol 2022;77(6):1545–1553CrossRefPubMed
13.
go back to reference de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII – Renewing consensus in portal hypertension. J Hepatol 2022;76(4):959–974CrossRefPubMed de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII – Renewing consensus in portal hypertension. J Hepatol 2022;76(4):959–974CrossRefPubMed
14.
go back to reference Hirschfield GM, Beuers U, Corpechot C, et al. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017;67(1):145–172CrossRef Hirschfield GM, Beuers U, Corpechot C, et al. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017;67(1):145–172CrossRef
17.
go back to reference Xu Y, Liu Y, Cao Z, et al. Comparison of FibroTouch and FibroScan for staging fibrosis in chronic liver disease: single-center prospective study. Dig Liver Dis 2019;51(9):1323–1329CrossRefPubMed Xu Y, Liu Y, Cao Z, et al. Comparison of FibroTouch and FibroScan for staging fibrosis in chronic liver disease: single-center prospective study. Dig Liver Dis 2019;51(9):1323–1329CrossRefPubMed
18.
go back to reference Zuo Z, Cui H, Wang M, et al. Diagnostic of FibroTouch and six serological models in assessing the degree of liver fibrosis among patients with chronic hepatic disease: a single-center retrospective study. PLoS One 2022;17(7): e270512 Zuo Z, Cui H, Wang M, et al. Diagnostic of FibroTouch and six serological models in assessing the degree of liver fibrosis among patients with chronic hepatic disease: a single-center retrospective study. PLoS One 2022;17(7): e270512
19.
go back to reference Qu Y, Song Y, Chen C, et al. Diagnostic performance of fibrotouch ultrasound attenuation parameter and liver stiffness measurement in assessing hepatic steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Clin Transl Gastroenterol 2021;12(4): e323CrossRef Qu Y, Song Y, Chen C, et al. Diagnostic performance of fibrotouch ultrasound attenuation parameter and liver stiffness measurement in assessing hepatic steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Clin Transl Gastroenterol 2021;12(4): e323CrossRef
20.
go back to reference Peng X, Tian A, Li J, et al. Diagnostic value of fibrotouch and non-invasive fibrosis indexes in hepatic fibrosis with different aetiologies. Dig Dis Sci 2022;67(6):2627–2636CrossRefPubMed Peng X, Tian A, Li J, et al. Diagnostic value of fibrotouch and non-invasive fibrosis indexes in hepatic fibrosis with different aetiologies. Dig Dis Sci 2022;67(6):2627–2636CrossRefPubMed
21.
go back to reference Ferraioli G, Maiocchi L, Lissandrin R, et al. Accuracy of the elastPQ® technique for the assessment of liver fibrosis in patients with chronic hepatitis c: a “real life” single center study. J Gastrointestin Liver Dis 2020;25(3):331–335CrossRef Ferraioli G, Maiocchi L, Lissandrin R, et al. Accuracy of the elastPQ® technique for the assessment of liver fibrosis in patients with chronic hepatitis c: a “real life” single center study. J Gastrointestin Liver Dis 2020;25(3):331–335CrossRef
22.
go back to reference Fang C, Jaffer OS, Yusuf GT, et al. Reducing the number of measurements in liver point shear-wave elastography: factors that influence the number and reliability of measurements in assessment of liver fibrosis in clinical practice. Radiology 2018;287(3):844–852CrossRefPubMed Fang C, Jaffer OS, Yusuf GT, et al. Reducing the number of measurements in liver point shear-wave elastography: factors that influence the number and reliability of measurements in assessment of liver fibrosis in clinical practice. Radiology 2018;287(3):844–852CrossRefPubMed
23.
go back to reference Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24(2):289–293CrossRefPubMed Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24(2):289–293CrossRefPubMed
25.
go back to reference Corpechot C, Chazouilleres O, Rousseau A, et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med 2018;378(23):2171–2181CrossRefPubMed Corpechot C, Chazouilleres O, Rousseau A, et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med 2018;378(23):2171–2181CrossRefPubMed
Metadata
Title
Prognostic significance of liver stiffness in patients with primary biliary cholangitis: validation of Baveno VII criteria
Authors
Dawei Ding
Guanya Guo
Lina Cui
Gui Jia
Xiufang Wang
Miao Zhang
Siyuan Tian
Linhua Zheng
Yansheng Liu
Yinan Hu
Guoyun Xuan
Jiaqi Yang
Chunmei Yang
Ruiqing Sun
Juan Deng
Changcun Guo
Yu Chen
Yulong Shang
Ying Han
Publication date
19-09-2023
Publisher
Springer India
Published in
Hepatology International / Issue 1/2024
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-023-10587-w

Other articles of this Issue 1/2024

Hepatology International 1/2024 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.